Subscribe to RSS

DOI: 10.1055/s-0045-1801890
Prognostic Factor Associated with Pre- and Postneoadjuvant Carcinoembryonic Antigen in Patients with Middle and Low Rectal Adenocarcinoma and its Correlation with Pathological Findings
Authors
Funding The author(s) received no financial support for the research.
Abstract
Introduction
Colorectal cancer (CRC) ranks among the top three most common cancers in Brazil, and the carcinoembryonic antigen (CEA) is one of the most used and established methods for prognostic evaluation and recurrence monitoring in CRC patients.
Objective
To analyze the pre- and postneoadjuvant levels of CEA in patients with middle or low rectal adenocarcinoma who underwent elective retossigmoidectomy with total mesorectal excision or abdominoperineal amputation of the rectum and to correlate the differences in pre- and postneoadjuvant CEA levels with the pathological staging.
Materials and Methods
Retrospective analysis of patients over 18 years old who underwent elective retossigmoidectomy with total mesorectal excision or abdominoperineal resection of the rectum. Data regarding age, sex, type of surgery, absolute CEA values, and differences in pre- and postneoadjuvant CEA levels were evaluated.
Results
The electronic medical records of 77 patients diagnosed with middle or low rectal adenocarcinoma who underwent surgery were analyzed. The mean pre- and postneoadjuvant levels of CEA were of 15.21(± 26.41) ng/mL and 7.17(± 15.6) ng/mL respectively, indicating a statistically significant decrease (p = 0.00058). The cutoff value for the analysis of neoplastic invasion depth (T) was determined to be 4.9 ng/mL, with a sensitivity of 73%, specificity of 63%, positive predictive value of 81%, and accuracy of 66.7%. For disease stage N, a cutoff value of 16.5 ng/mL was used. In this sample, the CEA test showed that the sensitivity and specificity for identifying patients with positive N disease were 41% and 89%, respectively, with a positive predictive value of 70% and an accuracy of 59.7%.
Conclusion
Carcinoembryonic antigen levels significantly decreased after neoadjuvant therapy in patients with middle and low rectal cancer. Pretreatment CEA levels were primarily associated with tumor invasion depth.
Authors' Contributions
Isaac José Felippe Corrêa Neto was responsible for drafting the article and conducting an analysis of the literature. Matheus Iguera Cirqueira, Gabriela Portal Monteiro, and Yasmin Gois de Mello contributed to the identification of study patients and the analysis of electronic medical records, ensuring the precision and organization of clinical data. Gabriel Fiorot Cruz Sperandio carried out the bibliographic review and the initial revision of the manuscript. Victor Keniti Gomes Nishiyama played a role in statistical analysis, ensuring methodological rigor in the results. Rodrigo Ambar Pinto collaborated on the initial revision and provided a critical analysis of the literature, strengthening the theoretical foundation of the article. Laercio Robles was responsible for the final revision and approval of the manuscript, ensuring its quality before completion.
Publication History
Received: 04 October 2024
Accepted: 29 October 2024
Article published online:
29 December 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)
Thieme Revinter Publicações Ltda.
Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil
Isaac José Felippe Corrêa Neto, Matheus Iguera Cirqueira, Gabriel Fiorot Cruz Sperandio, Gabriela Portal Monteiro, Yasmin Gois de Mello, Victor Keniti Gomes Nishiyama, Rodrigo Ambar Pinto, Laercio Robles. Prognostic Factor Associated with Pre- and Postneoadjuvant Carcinoembryonic Antigen in Patients with Middle and Low Rectal Adenocarcinoma and its Correlation with Pathological Findings. Journal of Coloproctology 2025; 45: s00451801890.
DOI: 10.1055/s-0045-1801890
-
References
- 1 Ministério da Saúde Instituto Nacional de Câncer José Alencar Gomes da Silva Ministério da Saúde Instituto Nacional de Câncer. Estimativa 2023 Incidência de câncer no Brasil. 2023.
- 2 Pucci MD, Dasenbrock A, Tanzawa CK, dos Santos MB. Perfil Clínico-Epidemiológico do Câncer Colorretal na Região Oeste do Paraná, Brasil, 2016–2018. Rev Bras Cancerol 2023; 69 (01) e113143
- 3 Yan C, Hu Y, Zhang B. et al. The CEA-/lo colorectal cancer cell population harbors cancer stem cells and metastatic cells. Oncotarget 2016; 7 (49) 80700-80715
- 4 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71 (03) 209-249
- 5 Konishi T, Shimada Y, Hsu M. et al. Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome. JAMA Oncol 2018; 4 (03) 309-315
- 6 Zi-Yang Y, Kaixun Z, Dongling L. et al. Carcinoembryonic antigen levels are increased with pulmonary output in pulmonary hypertension due to congenital heart disease. J Int Med Res 2020; 48 (11) 300060520964378
- 7 Ozawa T, Matsuda K, Ishihara S. et al. The robust performance of carcinoembryonic antigen levels after adjuvant chemotherapy for the recurrence risk stratification in patients with colorectal cancer. J Surg Oncol 2021; 124 (01) 97-105
- 8 Gao Y, Wang J, Zhou Y, Sheng S, Qian SY, Huo X. Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer. Sci Rep 2018; 8 (01) 2732
- 9 Campos-da-Paz M, Dórea JG, Galdino AS, Lacava ZGM, de Fatima Menezes Almeida Santos M. Carcinoembryonic Antigen (CEA) and Hepatic Metastasis in Colorectal Cancer: Update on Biomarker for Clinical and Biotechnological Approaches. Recent Pat Biotechnol 2018; 12 (04) 269-279
- 10 Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?. Clin Chem 2001; 47 (04) 624-630
- 11 Fernandes LC, Matos D. Marcadores tumorais no câncer colorretal. Rev Col Bras Cir 2002; 29 (02) 106-111
- 12 Moura RM, Matos D, Galvão Filho MM, D'Ippólito G, Sjzenfeld J, Giuliano LM. Value of CEA level determination in gallbladder bile in the diagnosis of liver metastases secondary to colorectal adenocarcinoma. Sao Paulo Med J 2001; 119 (03) 110-113
- 13 Compton CC. Colorectal carcinoma: diagnostic, prognostic, and molecular features. Mod Pathol 2003; 16 (04) 376-388
- 14 Solimene ACC, Carneiro CRW, Melati I, Lopes JD. Functional differences between two morphologically distinct cell subpopulations within a human colorectal carcinoma cell line. Braz J Med Biol Res 2001; 34 (05) 653-661
- 15 Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz R. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res 2000; 20 (6D): 5195-5198
- 16 Priolli DG, Cardinalli IA, Piovesan H, Margarido NF, Martinez CAR. Proposta para estadiamento do câncer colorretal baseada em critérios morfofuncionais: correlação com níveis séricos do antígeno carcinoembrionário. Rev Bras Coloproctol 2007; 27 (04) 374-383
- 17 Liu Y, Chen J. Expression Levels and Clinical Significance of Serum miR-497, CEA, CA24-2, and HBsAg in Patients with Colorectal Cancer. BioMed Res Int 2022; 2022: 3541403
- 18 Xu T, Yu Z, Zhang Q, Liu B, Li Y, Wang F. Prognostic and staging value of tumor deposits in patients with rectal cancer after neoadjuvant chemoradiotherapy. Transl Cancer Res 2021; 10 (12) 5028-5039
- 19 Engineer R, Basu T, Chopra S. et al. Factors influencing response to neoadjuvant chemoradiation and outcomes in rectal cancer patients: tertiary Indian cancer hospital experience. J Gastrointest Oncol 2015; 6 (02) 155-164
- 20 Liu GC, Zhang X, Xie E. et al. The Value of Restaging With Chest and Abdominal CT/MRI Scan After Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. Medicine (Baltimore) 2015; 94 (47) e2074
- 21 Zhou C, Wang K, Zhang X. et al. Assessing the predictive value of clinical factors to pathological complete response for locally advanced rectal cancer: An analysis of 124 patients. Front Oncol 2023; 13: 1125470
